VistaGen Therapeutics Reports Second Fiscal Quarter 2018

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
144
VistaGen Therapeutics Reports Second Fiscal Quarter 2018 Financial Results and Provides Business Update

SOUTH SAN FRANCISCO, CA --(Marketwired - November 09, 2017) - VistaGen Therapeutics Inc. ( NASDAQ : VTGN ), a clinical-stage biopharmaceutical company focused on developing new generation medicines for depression and other central nervous system (CNS) disorders, today reported its financial results for its second fiscal quarter ended September 30, 2017.

The Company also provided an update on its corporate progress and recently achieved milestone for AV-101, its oral CNS drug candidate in Phase 2 development, initially as a new generation adjunctive treatment for major depressive disorder (MDD).

"The FDA's recent authorization to proceed under our AV-101 IND application is a significant milestone in our Phase 2 program focused on MDD," commented Shawn Singh, Chief Executive Officer of VistaGen . "With that authorization, we are now one step closer towards our goal of commencing our 180-patient, multi-center, double-blind, placebo-controlled Phase 2 adjunctive treatment study in the first quarter of 2018."

Milestones achieved during the quarter: In October 2017, the U.S. Food and Drug Administration (FDA) authorized the Company to proceed under its Investigational New Drug (IND) application with its planned 180-patient, multi-center, double-blind, placebo-controlled Phase 2 study to assess the safety, tolerability and efficacy of AV-101 as an orally administered adjunctive treatment for adult MDD patients with an inadequate response to standard, FDA-approved antidepressants. Dr. Maurizio Fava of Harvard Medical School will be the Principal Investigator of this study, expected to begin in the first quarter of 2018 with completion expected at the end of 2018.

Recent Operational Highlights: Intellectual Property Accomplishments

  • The European Patent Office granted a European Patent for AV-101 relating to the treatment of depression, Parkinson's disease levodopa-induced dyskinesia (PD LID) and use of multiple dosage forms to treat these CNS disorders. The patent has been validated in Belgium, Denmark, France, Germany, Ireland, Italy, Portugal, Spain, Switzerland and the United Kingdom. It will be in effect until January 2034.
  • The Company received a Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application No. 14/775,287 related to certain methods of production for AV-101.
  • The corresponding patent application related to methods of production for AV-101 was also granted in China.

Bolstered Clinical Team with Industry Expert

  • The Company appointed David Rotella, Ph.D. to the Scientific Advisory Board of VistaStem Therapeutics , the Company's wholly owned subsidiary focused on utilizing the Company's stem cell technology, to assist in advancing VistaStem's small molecule drug rescue objectives and in evaluating other CNS-focused programs intended to expand VistaGen's drug development pipeline. Dr. Rotella has extensive academic research and pharmaceutical industry experience in both medicinal chemistry and drug discovery, including key leadership roles on teams at Wyeth, Pfizer and Bristol-Meyers focused on drug candidates to fight cancer, cardiovascular disease, metabolic disorders, and neurodegenerative diseases.

Financial Results for the Fiscal Quarter Ended September 30, 2017: Net loss for the fiscal quarter ended September 30, 2017 was approximately $5.0 million, including non-cash expenses of approximately $2.1 million, compared to $3.1 million for the fiscal quarter ended September 30, 2016, which included non-cash expenses of approximately $0.7 million.

Research and development expense totaled approximately $2.4 million for the fiscal quarter ended September 30, 2017, compared with approximately $1.6 million for the fiscal quarter ended September 30, 2016. The increase in year-over-year research and development expense was attributable to the Company's increased focus on the continuing nonclinical and clinical development of AV-101 and ongoing preparations to launch its AV-101 MDD Phase 2 adjunctive treatment study.

General and administrative expense was approximately $2.6 million in the fiscal quarter ended September 30, 2017, compared to approximately $1.5 million in the fiscal quarter ended September 30, 2016, reflecting increased professional services expenses and noncash expense attributable to the grant of common stock for services, noncash warrant modification expense and, to a lesser extent, salary and benefits and noncash stock compensation expenses.

At September 30, 2017, the Company had cash of approximately $1.76 million, compared to approximately $1.63 million as of June 30, 2017. In September 2017, the Company completed an underwritten public offering of shares of its common stock and warrants. The gross proceeds from this offering were approximately $2.4 million, resulting in net proceeds of $2.0 million, after deducting the underwriting discount and offering expenses.

About VistaGen VistaGen Therapeutics, Inc. ( NASDAQ : VTGN ) is a clinical-stage biopharmaceutical company focused on developing new generation medicines for depression and other CNS disorders. VistaGen's lead CNS product candidate, AV-101, is in Phase 2 development, initially as a new generation oral antidepressant drug candidate for MDD. AV-101's mechanism of action is fundamentally different from all FDA-approved antidepressants and atypical antipsychotics used adjunctively to treat MDD, with potential to drive a paradigm shift towards a new generation of safer and faster-acting antidepressants. AV-101 is currently being evaluated by the NIMH in a small Phase 2 monotherapy study in MDD being fully funded by the NIMH and conducted by Dr. Carlos Zarate Jr., Chief, Section on the Neurobiology and Treatment of Mood Disorders and Chief of Experimental Therapeutics and Pathophysiology Branch at the NIMH. VistaGen is preparing to launch a 180-patient Phase 2 study of AV-101 as an adjunctive treatment for MDD patients with an inadequate response to standard, FDA-approved antidepressants, with Dr. Maurizio Fava of Harvard University as Principal Investigator. AV-101 may also have the potential to treat multiple CNS disorders and neurodegenerative diseases in addition to MDD, including neuropathic pain, epilepsy, Huntington's disease, PD LID and other disorders where modulation of the NMDA receptors, activation of AMPA pathways and/or key active metabolites of AV-101 may achieve therapeutic benefit.

About VistaStem VistaStem Therapeutics is VistaGen's wholly-owned subsidiary focused on applying human pluripotent stem cell (hPSC) technology, internally and with third-party collaborators, to discover, rescue, develop and commercialize (i) proprietary new chemical entities (NCEs), including NCEs with regenerative potential, for CNS and other diseases and (ii) cellular therapies involving stem cell-derived blood, cartilage, heart and liver cells. VistaStem's internal drug rescue programs are designed to utilize CardioSafe 3D, its customized cardiac bioassay system, to develop NCEs for VistaGen's pipeline. To advance potential regenerative medicine (RM) applications of its cardiac stem cell technology, in December 2016, VistaStem exclusively sublicensed to BlueRock Therapeutics LP, a next generation regenerative medicine company established in 2016 by Bayer AG and Versant Ventures, rights to certain proprietary technologies relating to the production of cardiac cells for the treatment of heart disease. In a manner similar to its exclusive sublicense agreement with BlueRock Therapeutics, VistaStem may pursue additional collaborations and potential RM applications of its stem cell technology platform, including using blood, cartilage, and/or liver cells derived from hPSCs, for (i) cell-based therapy, (ii) cell repair therapy, and/or (iii) tissue engineering.

For more information, please visit www.vistagen.com and connect with VistaGen on Twitter , LinkedIn and Facebook .

Forward-Looking Statements The statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks related to the successful funding, launch, continuation and results of the NIMH's Phase 2 (monotherapy) and/or the Company's planned Phase 2 (adjunctive treatment) clinical studies of AV-101 in MDD, and other CNS diseases and disorders, including neuropathic pain and PD LID, protection of its intellectual property, and the availability of substantial additional capital to support its operations, including the AV-101 Phase 2 adjunctive treatment study and other potential AV-101 clinical development activities described above. These and other risks and uncertainties are identified and described in more detail in VistaGen's filings with the Securities and Exchange Commission (SEC). These filings are available on the SEC's website at www.sec.gov . VistaGen undertakes no obligation to publicly update or revise any forward-looking statements.

   
VISTAGEN THERAPEUTICS  
Condensed Consolidated Balance Sheets  
Amounts in Dollars  
           
  September 30,     March 31,  
  2017     2017  
  (Unaudited)        
           
ASSETS          
Current assets:          
  Cash and cash equivalents $ 1,764,400     $ 2,921,300  
  Prepaid expenses and other current assets 563,300     456,600  
    Total current assets 2,327,700     3,377,900  
Property and equipment, net 242,000     286,500  
Security deposits and other assets 47,800     47,800  
    Total assets $ 2,617,500     $ 3,712,200  
           
LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)          
Current liabilities:          
  Accounts payable $ 1,151,000     $ 867,300  
  Accrued expenses 625,600     443,000  
  Current notes payable 105,200     54,800  
  Capital lease obligations 2,500     2,400  
    Total current liabilities 1,884,300     1,367,500  
           
Non-current liabilities:          
  Accrued dividends on Series B Preferred Stock 2,081,400     1,577,800  
  Deferred rent liability 312,700     139,200  
  Capital lease obligations 10,700     11,900  
    Total non-current liabilities 2,404,800     1,728,900  
    Total liabilities 4,289,100     3,096,400  
           
Commitments and contingencies          
           
Stockholders' equity (deficit):          
  Preferred stock, $0.001 par value; 10,000,000 shares authorized at September 30, 2017 and March 31, 2017:          
    Series A Preferred, 500,000 shares authorized, issued and outstanding at September 30, 2017 and March 31, 2017 500     500  
    Series B Preferred; 4,000,000 shares authorized at September 30, 2017 and March 31, 2017; 1,160,240 shares issued and outstanding at September 30, 2017 and March 31, 2017 1,200     1,200  
    Series C Preferred; 3,000,000 shares authorized at September 30, 2017 and March 31, 2017; 2,318,012 shares issued and outstanding at September 30, 2017 and March 31, 2017 2,300     2,300  
  Common stock, $0.001 par value; 100,000,000 and 30,000,000 shares authorized at September 30, 2017 and          
    March 31, 2017, respectively; 11,764,639 and 8,974,386 shares issued at September 30, 2017 and          
    March 31, 2017, respectively 11,800     9,000  
  Additional paid-in capital 151,541,700     146,569,600  
  Treasury stock, at cost, 135,665 shares of common stock held at September 30, 2017 and March 31, 2017 (3,968,100 )   (3,968,100 )
  Accumulated deficit (149,261,000 )   (141,998,700 )
    Total stockholders' equity (deficit) (1,671,600 )   615,800  
    Total liabilities and stockholders' equity (deficit) $ 2,617,500     $ 3,712,200  
  
VISTAGEN THERAPEUTICS  
STATEMENT OF OPERATIONS  
Amounts in Dollars, except share amounts 
  
UNAUDITED  
  
  Three Months Ended September 30,     Six Months Ended September 30,  
  2017     2016     2017     2016  
Operating expenses:                      
  Research and development $ 2,426,600     $ 1,606,100     $ 3,522,800     $ 2,431,800  
  General and administrative 2,567,100     1,493,600     3,731,400     2,631,200  
    Total operating expenses 4,993,700     3,099,700     7,254,200     5,063,000  
Loss from operations (4,993,700 )   (3,099,700 )   (7,254,200 )   (5,063,000 )
Other expenses, net:                      
  Interest expense, net (3,300 )   (1,400 )   (5,700 )   (2,800 )
                       
Loss before income taxes (4,997,000 )   (3,101,100 )   (7,259,900 )   (5,065,800 )
Income taxes -     -     (2,400 )   (2,400 )
Net loss and comprehensive loss (4,997,000 )   (3,101,100 )   (7,262,300 )   (5,068,200 )
                       
  Accrued dividend on Series B Preferred stock (256,300 )   (241,000 )   (503,600 )   (780,800 )
  Deemed dividend on Series B Preferred Units -     -     -     (111,100 )
                       
Net loss attributable to common stockholders $ (5,253,300 )   $ (3,342,100 )   $ (7,765,900 )   $ (5,960,100 )
                       
Basic and diluted net loss attributable to common stockholders per common share $ (0.53 )   $ (0.42 )   $ (0.82 )   $ (0.91 )
                       
Weighted average shares used in computing basic and diluted net loss attributable to common stockholders per common share 9,892,016     8,041,619     9,465,459     6,577,769  
           
  Three Months Ended September 30,  
  2017     2016  
           
Operating expenses:          
  Research and development $ 2,427     $ 1,606  
  General and administrative 2,567     1,494  
    Total operating expenses 4,994     3,100  
           
Loss from operations (4,994 )   (3,100 )
           
Interest expense, net (3 )   (1 )
           
Loss before income taxes (4,997 )   (3,101 )
Income taxes -     -  
           
Net loss $ (4,997 )   $ (3,101 )
  Accrued dividend on Series B Preferred Stock (256 )   (241 )
  Deemed dividend on Series B Preferred Stock -     -  
Net loss attributable to common stockholders $ (5,253 )   $ (3,342 )
           
  Six Months Ended September 30,  
  2017     2016  
           
Operating expenses:          
  Research and development $ 3,523     $ 2,432  
  General and administrative 3,731     2,631  
    Total operating expenses 7,254     5,063  
           
Loss from operations (7,254 )   (5,063 )
           
Interest expense (net) (6 )   (3 )
           
Loss before income taxes (7,260 )   (5,066 )
Income taxes (2 )   (2 )
           
Net loss $ (7,262 )   $ (5,068 )
  Accrued dividend on Series B Preferred Stock (504 )   (781 )
  Deemed dividend on Series B Preferred Stock -     (111 )
Net loss attributable to common stockholders $ (7,766 )   $ (5,960 )

Company Contact Mark A. McPartland VistaGen Therapeutics Inc. Phone: +1 (650) 577-3600 Email: IR@vistagen.com Investor Contact: Valter Pinto / Allison Soss KCSA Strategic Communications Phone: +1 (212) 896-1254/+1 (212) 896-1267 Email: VistaGen@KCSA.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

COP31 Puts China’s Weather-to-Energy Model on View

Updated Category News Views 76

Storm maps are becoming operating manuals, and that is the hard reality behind a November 13 COP31 event in Antalya, Türkiye. The session, “From Early Warning to Energy Action: Pathways for Global Climate Diplomacy and Cooperation,” put China’s effort to tie meteorological intelligence to energy-system decisions under an international spotlight. This is not...

Continue Reading
Teachstone’s Bronze Award Puts Classroom Quality in Focus

Updated Category News Views 0

Small Classroom Moments Finally Get Their Due A child’s hesitant question can disappear in the noise of a busy classroom, which is precisely why Teachstone’s latest recognition deserves more than the usual polite golf clap. The Charlottesville-based Certified B Corporation received a Bronze Anthem Award for its “From Measurement to Momentum” initiative, in the...

Continue Reading
Sogroya Approval Broadens Novo's Pediatric Growth Franchise

Updated Category News Views 14

Seven fewer injections every week is the real headline behind Novo Nordisk's latest FDA clearance, not some flashy efficacy leap. On November 20, 2026, the company said Sogroya, its once-weekly long-acting growth hormone, won approval for children aged 2.5 and older with growth failure associated with Turner syndrome. That matters because treatment can stretch over years,...

Continue Reading
AMD Faces Fresh Scrutiny Over China Supply Exposure

Updated Category News Views 18

One nasty report can turn a chip giant’s supply chain into a flashing red light, and that is precisely the mess confronting Advanced Micro Devices investors this week. Shares fell more than 7.7% on November 19 after Hunterbrook Media published allegations involving China-linked sales, firmware and manufacturing relationships. Then, on November 20, shareholder-rights...

Continue Reading
KidneyVoter Push Turns Patient Frustration Into Clout

Updated Category News Views 84

A ballot registration drive rarely tells the whole story, but it can reveal where the pressure is building. The American Association of Kidney Patients says its 2026 nonpartisan KidneyVoter™ effort, “50 States in 50 Days,” reached constituencies in every state after launching September 14. That does not produce a clean vote total or prove legislators will suddenly...

Continue Reading
Pinnacol’s Community Work Earns Denver Chamber Recognition

Updated Category News Views 27

A workers’ comp insurer usually becomes visible on somebody’s worst day; Pinnacol Assurance is being recognized for the work it keeps doing around those days. The Denver Metro Chamber of Commerce has given the Colorado-based, member-owned carrier its 2026 Business Impact Award for Corporate Social Responsibility. Awards can be cheap applause, frankly. This one...

Continue Reading
CASEKOO's Montana Story Makes Brand Purpose Personal

Updated Category News Views 19

A blurry Montana kitchen, not a glossy product render, is doing the heavy lifting for CASEKOO this Thanksgiving. That is either a smart bit of brand discipline or a sentimental detour, depending on whether the company can make people feel something without losing sight of why they bought a phone case in the first place. Warmth Takes the Place of Hardware CASEKOO's new...

Continue Reading
Pennsylvania Housing Finds Its October Holding Pattern

Updated Category News Views 79

Pennsylvania's October housing numbers have the uneasy stillness of a pond before somebody throws a rock. The statewide median sales price sat at $315,000, exactly where it was in September, while sales barely cleared 10,400 and available listings kept inching higher. Nothing in that mix screams boom or bust. Frankly, that is the point: a market can look calm on the...

Continue Reading
Fervo IPO Lawsuit Puts 71% Share Collapse in Focus

Updated Category News Views 36

Fervo’s $27 debut has turned into the sort of wreckage IPO buyers dread: shares were alleged to have closed as low as $7.79 when the complaint was filed. That is more than a 71% fall from the May 13, 2026 offering price, and it puts a hard, ugly number beside the new securities class action against the geothermal power developer. More Than a Bad Quarter Is Being Alleged...

Continue Reading
Trip.Best Expands Global Travel Discovery Footprint

Updated Category News Views 123

Sydney just became the map pin for a fairly serious travel-content land grab. Trip.Best, Trip.com Group's ranking brand, has rolled out its 2027 Annual Rankings with coverage of all seven continents for the first time. This is not an earnings release, and nobody should pretend a hotel list magically turns into revenue by lunchtime. Still, the jump from 85 to 98 annual...

Continue Reading

Top 5 Most Recently Viewed Articles

3D Marketing & Services, LLC Enhances Global Presence with RADIUM

Updated Category News Views 149

3D Marketing & Services, LLC Enhances Global Presence with RADIUM LIMITED In an exciting development, 3D Marketing & Services, LLC, a dynamic digital marketing and media distribution agency, proudly announces a transformative partnership with RADIUM LIMITED. This collaboration marks a significant growth milestone for 3D Marketing, emphasizing their commitment to deliver...

Continue Reading
Aerospace Riveting Equipment Market Expected to Surge

Updated Category News Views 88

Aerospace Riveting Equipment Market Expected to Surge The aerospace riveting equipment market is on an impressive growth trajectory. Estimates indicate that this sector, valued at USD 109 million in 2023, could reach as high as USD 134 million by 2028, expanding at a compound annual growth rate (CAGR) of 4.3% during this period. Numerous factors contribute to robust...

Continue Reading
Kinetic Seas CEO Edward Honour Reflects on Last Year's Growth

Updated Category News Views 309

Kinetic Seas CEO Edward Honour Reflects on Last Year's Growth Kinetic Seas (OTC: KSEZ) has charted a remarkable journey since we took operational control just over a year ago. I am Edward Honour, your CEO and Chairman of the Board. In this letter, I will share the inspiring story of our company's evolution and the challenges we overcame along the way. Our Vision and...

Continue Reading
Investigation into The Greenbrier Companies, Inc. by Investors

Updated Category News Views 351

Investigation Overview of The Greenbrier Companies Pomerantz LLP is currently conducting an investigation on behalf of the investors of The Greenbrier Companies, Inc. (NYSE: GBX). This inquiry seeks to uncover any possible securities fraud or unlawful practices involving the company's executives. Company Financial Performance The investigation follows Greenbrier's...

Continue Reading
Exploring Charles Schwab's Remarkable Growth Over Two Decades

Updated Category News Views 169

The Growth of Charles Schwab Over Twenty Years Charles Schwab (NYSE: SCHW) has shown remarkable performance over the last two decades, consistently outperforming the market. With an annualized growth rate that eclipses broader market returns by 1.21%, investors have witnessed an impressive average annual return of 10.08%. Investment Value After 20 Years Imagine if an...

Continue Reading